Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pacira Pharmaceuticals ( (PCRX) ) has provided an announcement.
On January 21, 2025, Pacira BioSciences announced two key leadership appointments with Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer, to advance the company’s transition into an innovative biopharmaceutical organization. These appointments are part of Pacira’s strategy to grow its commercial business and enhance its pipeline, supporting its 5×30 growth initiative. Additionally, the company amended its 2014 Inducement Plan, reserving more shares for new employees and extending the plan’s term to 2035, which could attract new talent and support its operational goals.
More about Pacira Pharmaceuticals
Pacira BioSciences, Inc. is an industry leader in providing innovative, non-opioid pain therapies. The company offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera°. EXPAREL® is a long-acting local analgesic approved for various nerve blocks and pain management applications, ZILRETTA® is an extended-release injection for osteoarthritis knee pain, and iovera° is a device for drug-free pain control. Pacira is advancing the development of PCRX-201, a gene therapy for osteoarthritis, underscoring its commitment to transforming patient lives.
YTD Price Performance: 21.99%
Average Trading Volume: 715,928
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.03B
For a thorough assessment of PCRX stock, go to TipRanks’ Stock Analysis page.
